#IFW

/TO/SB/21 (08-00),
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → [+]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/918,365
Filing Date	July 30, 2001
First Named Inventor	Eugene T. Michal
Group Art Unit	1762
Examiner Name	Unassigned
Total Number of Pages in This Submission (excluding references) 18	**Attorney Docket No.** 50623.379

ENCLOSURES *(check all that apply)*

- ☒ Deposit Account Authorization 07-1850
- ☒ Postage Paid Return Postcard
- ☐ Response to Office Action
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Petition for Extension of Time (__ month) (in duplicate)
- ☐ Amendment Transmittal Letter (in duplicate)
- ☒ Information Disclosure Statement (2 pages – in duplicate) with Form PTO-1449 citing 342 References (12 pages)
- ☐ Request for Continued Examination (RCE) Transmittal
- ☐ Express Mail Label No.
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Formal Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) ____
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Submission of Formal Drawings (in duplicate)
- ☒ Other Enclosure(s) *(please identify below)*:
  342 References

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm *or* Individual name	Squire, Sanders & Dempsey L.L.P. Zhaoyang Li, Ph.D., Reg. No. 46,872
Signature	
Date	September 22 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name	Evelyn Quan		
Signature		Date	September 23, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT ($) 180.00

Complete if Known	
Application Number	09/918,365
Filing Date	July 30, 2001
First Named Inventor	Eugene T. Michal
Examiner Name	Jennifer K. Michener
Art Unit	1762
Attorney Docket No.	50623.379

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number: 07-1850

Deposit Account Name: Squire, Sanders & Dempsey L.L.P.

The Director is authorized to: *(check all that apply)*
☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, **except for the filing fee** to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) ($)

2. EXTRA CLAIM FEES

		Extra Claims	Fee from below		Fee Paid
Total Claims				=	
Independent Claims				=	
Multiple Dependent	0		X 0	=	

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3.
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) ($) .00

***or number previously paid, if greater; For Reissues, see above*

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	205	Extension for reply within second month	
1253	950	2253	465	Extension for reply within third month	
1254	1,480	2254	725	Extension for reply within fourth month	
1255	2,010	2255	985	Extension for reply within fifth month	
1401	330	2401	160	Notice of Appeal	
1402	330	2402	160	Filing a brief in support of an appeal	
1403	290	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive – unavoidable	
1453	1,300	2453	650	Petition to revive – unintentional	
1501	1,330	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid **SUBTOTAL (3)** ($)180.00

SUBMITTED BY				Complete *(if applicable)*	
Name (Print/Type)	Zhaoyang Li, Ph.D.	*Registration No. Attorney/Agent)*	46,872	*Telephone*	(415) 954-0200
Signature				*Date*	September 22 2005

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Michal et al.	Examiner:	Jennifer K. Michener
Serial No.	09/918,365	Art Unit:	1762
Filed:	July 30, 2001		
Title:	COVALENTLY IMMOBILIZED HEPARIN INTO AND ONTO FUNCTIONALIZED POLYURETHANE		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. Copies of the cited U.S. patents, U.S. Patent Application Publications, non published U.S. applications, cited foreign patent documents and non-patent literature have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being submitted after receiving the first office action but before an action closing prosecution on the merits. Accordingly, please charge Deposit Account No. 07-1850 in the amount of $180.00 as specified in 37 CFR §1.97(c) and 37 CFR §1.17(p). The Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: September 22, 2005

SQUIRE, SANDERS & DEMPSEY L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,



Zhaoyang Li, Ph.D.
Attorney for Applicants
Reg. No. 46,872

FORM PTO-1449 (Modified) US Patent and Trademark Office — US DEPARTMENT OF COMMERCE	Docket No. 50623.379	Application No. 09/918,365
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)	Applicant: Michal et al.	
	Filing Date: July 30, 2001	Group Art Unit: 1762

U.S. PATENT DOCUMENTS

Examiner Initial	Ref No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	2,072,303	3/2/37	Herrmann et al.			
	A2	2,386,454	10/9/45	Frosch et al.			
	A3	3,773,737	11/20/73	Goodman et al.			
	A4	3,849,514	11/19/74	Gray, Jr. et al.			
	A5	4,226,243	10/7/80	Shalaby et al.			
	A6	4,329,383	5/11/82	Joh			
	A7	4,343,931	8/10/82	Barrows			
	A8	4,529,792	7/16/85	Barrows			
	A9	4,611,051	9/9/86	Hayes et al.			
	A10	4,656,242	4/7/87	Swan et al.			
	A11	4,733,665	3/29/88	Palmaz			
	A12	4,800,882	1/31/89	Gianturco			
	A13	4,882,168	11/21/89	Casey et al.			
	A14	4,886,062	12/12/89	Wiktor			
	A15	4,931,287	6/5/90	Bae et al.			
	A16	4,941,870	7/17/90	Okada et al.			
	A17	4,977,901	12/18/90	Ofstead			
	A18	5,019,096	5/28/91	Fox, Jr. et al.			
	A19	5,100,992	3/31/92	Cohn et al.			
	A20	5,112,457	5/12/92	Marchant			
	A21	5,133,742	7/28/92	Pinchuk			
	A22	5,163,952	11/17/92	Froix			
	A23	5,165,919	11/24/92	Sasaki et al.			
	A24	5,219,980	6/15/93	Swidler			
	A25	5,258,020	11/2/93	Froix			

	A26	5,272,012	12/21/93	Opolski			
	A27	5,292,516	3/8/94	Viegas et al.			
	A28	5,298,260	3/29/94	Viegas et al.			
	A29	5,300,295	4/5/94	Viegas et al.			
	A30	5,306,501	4/26/94	Viegas et al.			
	A31	5,306,786	4/26/94	Moens et al.			
	A32	5,328,471	7/12/94	Slepian			
	A33	5,330,768	7/19/94	Park et al.			
	A34	5,380,299	1/10/95	Fearnot et al.			
	A35	5,417,981	5/23/95	Endo et al.			
	A36	5,447,724	9/5/95	Helmus et al.			
	A37	5,455,040	10/3/95	Marchant			
	A38	5,462,990	10/31/95	Hubbell et al.			
	A39	5,464,650	11/7/95	Berg et al.			
	A40	5,485,496	1/16/96	Lee et al.			
	A41	5,516,881	5/14/96	Lee et al.			
	A42	5,569,463	10/29/96	Helmus et al.			
	A43	5,578,073	11/26/96	Haimovich et al.			
	A44	5,584,877	12/17/96	Miyake et al.			
	A45	5,605,696	2/25/97	Eury et al.			
	A46	5,607,467	3/4/97	Froix			
	A47	5,609,629	3/11/97	Fearnot et al.			
	A48	5,610,241	3/11/97	Lee et al.			
	A49	5,616,338	4/1/97	Fox, Jr. et al.			
	A50	5,624,411	4/29/97	Tuch			
	A51	5,628,730	5/13/97	Shapland et al.			
	A52	5,644,020	7/1/97	Timmermann et al.			
	A53	5,649,977	7/22/97	Campbell			
	A54	5,658,995	8/19/97	Kohn et al.			
	A55	5,667,767	9/16/97	Greff et al.			
	A56	5,670,558	9/23/97	Onishi et al.			
	A57	5,674,242	10/7/97	Phan et al.			

	A58	5,679,400	10/21/97	Tuch			
	A59	5,700,286	12/23/97	Tartaglia et al.			
	A60	5,702,754	12/30/97	Zhong			
	A61	5,711,958	1/27/98	Cohn et al.			
	A62	5,716,981	2/10/98	Hunter et al.			
	A63	5,721,131	2/24/98	Rudolph et al.			
	A64	5,723,219	3/3/98	Kolluri et al.			
	A65	5,735,897	4/7/98	Buirge			
	A66	5,746,998	5/5/98	Torchilin et al.			
	A67	5,759,205	6/2/98	Valentini			
	A68	5,776,184	7/7/98	Tuch			
	A69	5,783,657	7/21/98	Pavlin et al.			
	A70	5,788,979	8/4/98	Alt et al.			
	A71	5,800,392	9/1/98	Racchini			
	A72	5,820,917	10/13/98	Tuch			
	A73	5,824,048	10/20/98	Tuch			
	A74	5,824,049	10/20/98	Ragheb et al.			
	A75	5,830,178	11/3/98	Jones et al.			
	A76	5,837,008	11/17/98	Berg et al.			
	A77	5,837,313	11/17/98	Ding et al.			
	A78	5,849,859	12/15/98	Acemoglu			
	A79	5,851,508	12/22/98	Greff et al.			
	A80	5,854,376	12/29/98	Higashi			
	A81	5,857,998	1/12/99	Barry			
	A82	5,858,746	1/12/99	Hubbell et al.			
	A83	5,865,814	2/2/99	Tuch			
	A84	5,869,127	2/9/99	Zhong			
	A85	5,873,904	2/23/99	Ragheb et al.			
	A86	5,876,433	3/2/99	Lunn			
	A87	5,877,224	3/2/99	Brocchini et al.			
	A88	5,879,713	3/9/99	Roth et al.			
	A89	5,902,875	5/11/99	Roby et al.			

	A90	5,905,168	5/18/99	Dos Santos et al.			
	A91	5,910,564	6/8/99	Gruning et al.			
	A92	5,914,387	6/22/99	Roby et al.			
	A93	5,919,893	7/6/99	Roby et al.			
	A94	5,925,720	7/20/99	Kataoka et al.			
	A95	5,932,299	8/3/99	Katoot			
	A96	5,955,509	9/21/99	Webber et al.			
	A97	5,958,385	9/28/99	Tondeur et al.			
	A98	5,962,138	10/5/99	Kolluri et al.			
	A99	5,971,954	10/26/99	Conway et al.			
	A100	5,980,928	11/9/99	Terry			
	A101	5,980,972	11/9/99	Ding			
	A102	5,997,517	12/7/99	Whitbourne			
	A103	6,010,530	1/4/00	Goicoechea			
	A104	6,011,125	1/4/00	Lohmeijer et al.			
	A105	6,015,541	1/18/00	Greff et al.			
	A106	6,033,582	3/7/00	Lee et al.			
	A107	6,034,204	3/7/00	Mohr et al.			
	A108	6,042,875	3/28/00	Ding et al.			
	A109	6,051,576	4/18/00	Ashton et al.			
	A110	6,051,648	4/18/00	Rhee et al.			
	A111	6,054,553	4/25/00	Groth et al.			
	A112	6,056,993	5/2/00	Leidner et al.			
	A113	6,060,451	5/9/00	DiMaio et al.			
	A114	6,060,518	5/9/00	Kabanov et al.			
	A115	6,080,488	6/27/00	Hostettler et al.			
	A116	6,096,070	8/1/00	Ragheb et al.			
	A117	6,099,562	8/8/00	Ding et al.			
	A118	6,110,188	8/29/00	Narciso, Jr.			
	A119	6,110,483	8/29/00	Whitbourne et al.			
	A120	6,113,629	9/5/00	Ken			
	A121	6,120,491	9/19/00	Kohn et al.			

	A122	6,120,536	9/19/00	Ding et al.			
	A123	6,120,788	9/19/00	Barrows			
	A124	6,120,904	9/19/00	Hostettler et al.			
	A125	6,121,027	9/19/00	Clapper et al.			
	A126	6,129,761	10/10/00	Hubbell			
	A127	6,136,333	10/24/00	Cohn et al.			
	A128	6,143,354	11/7/00	Koulik et al.			
	A129	6,153,252	11/28/00	Hossainy et al.			
	A130	6,159,978	12/12/00	Myers et al.			
	A131	6,165,212	12/26/00	Dereume et al.			
	A132	6,172,167	1/9/01	Stapert et al.			
	A133	6,177,523	1/23/01	Reich et al.			
	A134	6,180,632	1/30/01	Myers et al.			
	A135	6,203,551	3/20/01	Wu			
	A136	6,211,249	4/3/01	Cohn et al.			
	A137	6,214,901	4/10/01	Chudzik et al.			
	A138	6,231,600	5/15/01	Zhong			
	A139	6,240,616	6/5/01	Yan			
	A140	6,245,753	6/12/01	Byun et al.			
	A141	6,245,760	6/12/01	He et al.			
	A142	6,248,129	6/19/01	Froix			
	A143	6,251,136	6/26/01	Guruwaiya et al.			
	A144	6,254,632	7/3/01	Wu et al.			
	A145	6,258,121	7/10/01	Yang et al.			
	A146	6,258,371	7/10/01	Koulik et al.			
	A147	6,262,034	7/17/01	Mathiowitz et al.			
	A148	6,270,788	8/7/01	Koulik et al.			
	A149	6,277,449	8/21/01	Kolluri et al.			
	A150	6,283,947	9/4/01	Mirzaee			
	A151	6,283,949	9/4/01	Roorda			
	A152	6,284,305	9/4/01	Ding et al.			

	A153	6,287,628	9/11/01	Hossainy et al.			
	A154	6,299,604	10/9/01	Ragheb et al.			
	A155	6,306,176	10/23/01	Whitbourne			
	A156	6,331,313	12/18/01	Wong et al.			
	A157	6,335,029	1/1/02	Kamath et al.			
	A158	6,344,035	2/5/02	Chudzik et al.			
	A159	6,346,110	2/12/02	Wu			
	A160	6,358,556	3/19/02	Ding et al.			
	A161	6,379,381	4/30/02	Hossainy et al.			
	A162	6,387,379	5/14/02	Goldberg et al.			
	A163	6,395,326	5/28/02	Castro et al.			
	A164	6,419,692	7/16/02	Yang et al.			
	A165	6,451,373	9/17/02	Hossainy et al.			
	A166	6,482,834	11/19/02	Spada et al.			
	A167	6,494,862	12/17/02	Ray et al.			
	A168	6,503,538	1/7/03	Chu et al.			
	A169	6,503,556	1/7/03	Harish et al.			
	A170	6,503,954	1/7/03	Bhat et al.			
	A171	6,506,437	1/14/03	Harish et al.			
	A172	6,524,347	2/25/03	Myers et al.			
	A173	6,527,801	3/4/03	Dutta			
	A174	6,527,863	3/4/03	Pacetti et al.			
	A175	6,528,526	3/4/03	Myers et al.			
	A176	6,530,950	3/11/03	Alvarado et al.			
	A177	6,530,951	3/11/03	Bates et al.			
	A178	6,540,776	4/1/03	Sanders Millare et al.			
	A179	6,544,223	4/8/03	Kokish			
	A180	6,544,543	4/8/03	Mandrusov et al.			
	A181	6,544,582	4/8/03	Yoe			
	A182	6,555,157	4/29/03	Hossainy			
	A183	6,558,733	5/6/03	Hossainy et al.			

	A184	6,565,659	5/20/03	Pacetti et al.			6/28/01
	A185	6,572,644	6/3/03	Moein			6/27/01
	A186	6,585,755	7/1/03	Jackson et al.			6/29/01
	A187	6,585,765	7/1/03	Hossainy et al.			6/29/00
	A188	6,585,926	7/1/03	Mirzaee			8/31/00
	A189	6,605,154	8/12/03	Villareal			5/31/01
	A190	6,623,448	9/23/03	Slater			3/30/01
	A191	6,625,486	9/23/03	Lundkvist et al.			4/11/01
	A192	6,645,135	11/11/03	Bhat			3/30/01
	A193	6,645,195	11/11/03	Bhat et al.			1/5/01
	A194	6,656,216	12/2/03	Hossainy et al.			6/29/01
	A195	6,656,506	12/2/03	Wu et al.			5/09/01
	A196	6,660,034	12/9/03	Mandrusov et al.			4/30/01
	A197	6,663,662	12/16/03	Pacetti et al.			12/28/00
	A198	6,666,880	12/23/03	Chiu et al.			6/19/01
	A199	6,673,154	1/6/04	Pacetti et al.			6/28/01
	A200	6,673,385	1/6/04	Ding et al.			6/28/01
	A201	6,689,099	2/10/04	Mirzaee			2/27/01
	A202	6,695,920	2/24/04	Pacetti et al.			6/27/01
	A203	6,706,013	3/16/04	Bhat et al.			6/29/01
	A204	6,712,845	3/30/04	Hossainy			4/24/01
	A205	6,713,119	3/30/04	Hossainy et al.			12/23/99
	A206	6,716,444	7/6/04	Castro et al.			9/28/00
	A207	6,740,040	5/25/04	Mandrusov et al.			1/30/01
	A208	6,743,462	6/1/04	Pacetti			5/31/01
	A209	6,749,626	6/15/04	Bhat et al.			11/17/00
	A210	6,758,859	7/6/04	Dang et al.			10/30/00
	A211	6,759,054	7/6/04	Chen et al.			12/28/00

	A212	6,764,505	7/20/04	Hossainy et al.			4/12/01
	A213	6,887,485	5/3/05	Fitzhugh et al.			5/25/01
	A214	6,899,731	5/31/05	Li et al.			1/2/01

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
	A215	2001/0051608	12/13/01	Mathiowitz et al.			10/15/98
	A216	2002/0077693	6/20/02	Barclay et al.			12/19/00
	A217	2001/0007083	7/5/01	Roorda			12/21/00
	A218	2002/0009604	1/24/02	Zamora et al.			12/21/00
	A219	2002/0120326	8/29/02	Michal			12/22/00
	A220	2001/0014717	8/16/01	Hossainy et al.			12/28/00
	A221	2001/0018469	8/30/01	Chen et al.			12/28/00
	A222	2002/0123801	9/5/02	Pacetti et al.			12/28/00
	A223	2002/0087123	7/4/02	Hossainy et al.			1/2/01
	A224	2003/0032767	2/13/03	Tada et al.			2/5/01
	A225	2001/0020011	9/6/01	Mathiowitz et al.			3/23/01
	A226	2002/0142039	10/3/02	Claude			3/30/01
	A227	2002/0155212	10/24/02	Hossainy			4/24/01
	A228	2001/0029351	10/11/01	Falotico et al.			5/7/01
	A229	2002/0005206	1/17/02	Falotico et al.			5/7/01
	A230	2002/0007213	1/17/02	Falotico et al.			5/7/01
	A231	2002/0007214	1/17/02	Falotico			5/7/01
	A232	2002/0007215	1/17/02	Falotico et al.			5/7/01
	A233	2002/0016625	2/7/02	Falotico et al.			5/7/01
	A234	2002/0032414	3/14/02	Ragheb et al.			5/7/01
	A235	2002/0188277	12/12/02	Roorda et al.			5/18/01
	A236	2002/0183581	12/5/02	Yoe et al.			5/31/01
	A237	2001/0037145	11/1/01	Guruwaiya et al.			6/21/01
	A238	2002/0165608	11/7/02	Llanos et al.			6/22/01
	A239	2002/0071822	6/13/02	Uhrich			7/27/01

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No

	B1	2001-190687	7/17/01	Japan (English Abstract)				
	B2	DE 42 24 401	1/27/94	Germany				
	B3	EP 0 301 856	2/1/89	EPO				
	B4	EP 0 396 429	11/7/90	EPO				
	B5	EP 0 514 406	11/25/92	EPO				
	B6	EP 0 604 022	6/29/94	EPO				
	B7	EP 0 623 354	11/9/94	EPO				
	B8	EP 0 665 023	8/2/95	EPO				
	B9	EP 0 701 802	3/20/96	EPO				
	B10	EP 0 716 836	6/19/96	EPO				
	B11	EP 0 809 999	12/3/97	EPO				
	B12	EP 0 832 655	4/1/98	EPO				
	B13	EP 0 850 651	7/1/98	EPO				
	B14	EP 0 879 595	11/25/98	EPO				
	B15	EP 0 910 584	4/28/99	EPO				
	B16	EP 0 923 953	6/23/99	EPO				
	B17	EP 0 953 320	11/3/99	EPO				
	B18	EP 0 970 711	1/12/00	EPO				
	B19	EP 0 982 041	3/1/00	EPO				
	B20	EP 1 023 879	8/2/00	EPO				
	B21	EP 1 192 957	4/3/02	EPO				
	B22	EP 1 273 314	1/8/03	EPO				
	B23	SU 790725	2/9/83	SU (English Abstract)				
	B24	SU 811750	9/23/83	SU (English Abstract)				
	B25	SU 872531	10/15/81	SU (English Abstract)				
	B26	SU 876663	10/30/81	SU (English Abstract)				
	B27	SU 905228	2/15/82	SU (English Abstract)				
	B28	SU 1016314	5/7/83	SU (English Abstract)				
	B29	SU 1293518	2/28/87	SU (English Abstract)				
	B30	WO 91/12846	9/5/91	PCT				
	B31	WO 94/09760	5/11/94	PCT				
	B32	WO 95/10989	4/27/95	PCT				

	B33	WO 95/24929	9/21/95	PCT				
	B34	WO 96/40174	12/19/96	PCT				
	B35	WO 97/10011	3/20/97	PCT				
	B36	WO 97/45105	12/4/97	PCT				
	B37	WO 97/46590	12/11/97	PCT				
	B38	WO 98/08463	3/5/98	PCT				
	B39	WO 98/17331	4/30/98	PCT				
	B40	WO 98/32398	7/30/98	PCT				
	B41	WO 98/36784	8/27/98	PCT				
	B42	WO 99/01118	1/14/99	PCT				
	B43	WO 99/38546	8/5/99	PCT				
	B44	WO 99/63981	12/16/99	PCT				
	B45	WO 00/02599	1/20/00	PCT				
	B46	WO 00/12147	3/9/00	PCT				
	B47	WO 00/18446	4/6/00	PCT				
	B48	WO 00/64506	11/2/00	PCT				
	B49	WO 01/01890	1/11/01	PCT				
	B50	WO 01/15751	3/8/01	PCT				
	B51	WO 01/17577	3/15/01	PCT				
	B52	WO 01/45763	6/28/01	PCT				
	B53	WO 01/49338	7/12/01	PCT				
	B54	WO 01/51027	7/19/01	PCT				
	B55	WO 01/74414	10/11/01	PCT				
	B56	WO 02/003890	1/17/02	PCT				
	B57	WO 02/026162	4/4/02	PCT				
	B58	WO 02/034311	5/2/02	PCT				
	B59	WO 02/056790	7/25/02	PCT				
	B60	WO 02/058753	8/1/02	PCT				
	B61	WO 02/102283	12/27/02	PCT				
	B62	WO 03/000308	1/3/03	PCT				
	B63	WO 03/022323	3/20/03	PCT				
	B64	WO 03/028780	4/10/03	PCT				

	B65	WO 03/037223	5/8/03	PCT				
	B66	WO 03/039612	5/15/03	PCT				
	B67	WO 03/080147	10/2/03	PCT				
	B68	WO 03/082368	10/9/03	PCT				
	B69	WO 04/000383	12/31/03	PCT				
	B70	WO 04/009145	1/29/04	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Anonymous, *Cardiologists Draw - Up The Dream Stent*, Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959, printed 8/25/03 (2 pages).
	C2	Anonymous, *Heparin-coated stents cut complications by 30%*, Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753, printed 8/25/03 (2 pages).
	C3	Anonymous, *Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent* (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
	C4	Anonymous, *Stenting continues to dominate cardiology*, Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752, printed 8/25/03 (2 pages).
	C5	Aoyagi et al., *Preparation of cross-linked aliphatic polyester and application to thermo-responsive material*, Journal of Controlled Release 32:87-96 (1994).
	C6	Barath et al., *Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury*, JACC 13(2): 252A (Abstract) (Feb. 1989).
	C7	Barbucci et al., *Coating of commercially available materials with a new heparinizable material*, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
	C8	Chung et al., *Inner core segment design for drug delivery control of thermo-responsive polymeric micelles*, Journal of Controlled Release 65:93-103 (2000).
	C9	Dev et al., *Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs*, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
	C10	Dichek et al., *Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells*, Circ. 80(5):1347-1353 (Nov. 1989).
	C11	Eigler et al., *Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin*, JACC, 4A (701-1), Abstract (Feb. 1994).
	C12	Helmus, *Overview of Biomedical Materials*, MRS Bulletin, pp. 33-38 (Sept. 1991).
	C13	Herdeg et al., *Antiproliferative Stent Coatings: Taxol and Related Compounds*, Semin. Intervent. Cardiol. 3:197-199 (1998).
	C14	Huang et al., *Biodegradable Polymers Derived from Aminoacids*, Macromol. Symp. 144, 7-32 (1999).
	C15	Inoue et al., *An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs*, Journal of Controlled Release 51:221-229 (1998).
	C16	Kataoka et al., *Block copolymer micelles as vehicles for drug delivery*, Journal of Controlled Release 24:119-132 (1993).
	C17	Katsarava et al., *Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α-amino acid)α,ω-Alkylene Diesters, and Aliphatic Dicarbolic Acids*, Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).
	C18	Levy et al., *Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants*, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).

	C19	Liu et al., *Drug release characteristics of unimolecular polymeric micelles*, Journal of Controlled Release 68:167-174 (2000).
	C20	Marconi et al., *Covalent bonding of heparin to a vinyl copolymer for biomedical applications*, Biomaterials 18(12):885-890 (1997).
	C21	Matsumaru et al., *Embolic Materials For Endovascular Treatment of Cerebral Lesions*, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C22	Miyazaki et al., *Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice*, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C23	Miyazawa et al., *Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat*, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C24	Nordrehaug et al., *A novel biocompatible coating applied to coronary stents*, EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C25	Ohsawa et al., *Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty*, American Heart Journal 136(6):1081-1087 (Dec. 1998).
	C26	Ozaki et al., *New Stent Technologies*, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C27	Pechar et al., *Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin*, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	C28	Peng et al., *Role of polymers in improving the results of stenting in coronary arteries*, Biomaterials 17:685-694 (1996).
	C29	Saotome, et al., *Novel Enzymatically Degradable Polymers Comprising α-Amino Acid, 1,2-Ethanediol, and Adipic Acid*, Chemistry Letters, pp. 21-24, (1991).
	C30	Shigeno, *Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor*, Chemical Abstract 125:212307 (1996).
	C31	van Beusekom et al., *Coronary stent coatings*, Coronary Artery Disease 5(7):590-596 (July 1994).
	C32	Wilensky et al., *Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries*, Trends Cardiovasc. Med. 3(5):163-170 (1993).
	C33	Yokoyama et al., *Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor*, Journal of Controlled Release 50:79-92 (1998).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.